ArticleFrontiers in ophthalmology2026
Assessment of the aggregate index of systemic inflammation in dyslipidemia with dry eye disease: a retrospective case-control.
Article in Frontiers in ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dyslipidemia (DLP) is characterized by high rates of occurrence of inflammation. One outcome of DLP development is dry eye disease (DED). The level of inflammation was assessed by identifying clinically relevant parameters in the complete blood count (CBC). In this study, the aim was to evaluate inflammation in DLP-DED patients using the aggregate index of systemic inflammation (AISI) and inflammatory biomarkers, including C-reactive protein (CRP). Methods: A total of 214 patients who had been clinically diagnosed with DLP at King Abdulaziz Medical City between 2016 and 2023 were randomly selected for retrospective analysis. The patients were allocated to one of two groups: DLP only as the control group and DLP with DED as the study group. Blood biomarker tests and demographic data were gathered and analyzed. The means, standard deviations, and medians of the blood results were calculated. Associations with lipid profile and inflammatory indicators were evaluated by Spearman's correlation analysis. Moreover, a multivariable logistic regression analysis was performed to assess the independent association between AISI and DED, controlling for age, gender, and body mass index (BMI). Results: The DLP-DED group demonstrated higher neutrophil and monocyte counts relative to the DLP group. In the DLP-DED group, AISI showed a positive correlation with CRP and a weak negative correlation with HDL and total cholesterol. Conclusions: AISI may indicate components of systemic inflammation in patients with dyslipidemia; however, it was not associated with dry eye disease following adjustment for confounding variables. Additional evaluation of its clinical value requires prospective research. Impact statement: Investigating inflammatory biomarkers in patients with dyslipidemia and dry eye disease may improve understanding of the pathogenesis and pave the way for novel therapeutic approaches to alleviate this debilitating condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.